Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Debt Repayment

Cash used to repay borrowings during the period.

Champions Oncology, Inc.NASDAQ: CSBR

Debt Repayment · Q3 FY2026 · quarter ended Jan 2026

Debt repayment growth accelerates

Q3 FY2026 debt repayment of $39K (cash outflow) rose 2.6% year over year, ahead of the -40.3% change in trailing-twelve-month debt repayment. Sequentially, it rose 0.0% from the prior quarter.

Context

  • Debt repayment amounted to 0.3% of revenue in FY2025, unchanged from a year earlier.
  • Debt repayment increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2.6% holds above the trailing-twelve-month pace of -40.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJan 2026
-$39K+0.0% QoQ
Last fiscal yearApr 2025
-$150K+2.7% YoY
LTMJan 2026
-$154K-40.3% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.6%——
1 year+2.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(150K) USD
Year-over-year change
-2.7%

Debt Repayment vs competitors

How CSBR compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -40.3% is the 3rd highest of 5, against a peer median of +18.1%.
  • Debt repayment amounts to 0.3% of revenue for CSBR, versus a peer median of 0.0%.
CSBR Competitors
Debt Repayment for CSBR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMAImageneBio IncLTM Mar 2026$15M USD———
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$10.36M USD-66.1%——
KLRSKalaris Therapeutics IncLTM Mar 2026$7.5M USD—+20.4%—
CSBRChampions Oncology, Inc.LTM Jan 2026$154K USD-40.3%—0.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$66K USD-63.7%——
IFRXInflaRx N.V.LTM Mar 2026€25.41K EUR+106.3%-0.6%86.6%
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD——0.0%
STROSutro Biopharma, Inc.LTM Mar 2026$0 USD——0.0%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$0 USD+100.0%-21.6%0.0%
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
Peer median (excluding CSBR) —+18.1%-0.6%0.0%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Net Income334K548K(5.34M)(7.28M)4.7M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
Deferred Income Tax49K01M00
Stock-Based Compensation598K912K864K1.12M654K
Change in Working Capital(4.17M)2.34M4.23M(3.82M)(621K)
Accounts Receivables(2.27M)(2.82M)1.31M(1.99M)(1.44M)
Inventory(1.1M)0000
Accounts Payables(1.25M)974K2.47M465K(1.75M)
Other Working Capital441K4.18M470K(2.3M)2.56M
Other Non-Cash Items323K1.07M952K1.98M1.01M
Operating Cash Flow(1.68M)6.5M3.96M(6.14M)7.39M
Capital Expenditures(3.28M)(2.38M)(2.87M)(836K)(389K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities112K0000
Investing Cash Flow(3.17M)(2.38M)(2.87M)(836K)(389K)
Debt Repayment(174K)00(146K)(150K)
Common Stock Issued1.37M207K85K253K320K
Common Stock Repurchased00(74K)(634K)0
Dividends Paid00000
Other Financing Activities0085K253K0
Financing Cash Flow1.2M207K11K(527K)170K
Effect of Forex Changes0017K00
Net Change in Cash(3.66M)4.32M1.11M(7.5M)7.17M
Free Cash Flow(4.96M)4.11M1.08M(6.97M)7M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.